Zacks: Brokerages Expect BioCryst Pharmaceuticals, Inc. (BCRX) Will Post Quarterly Sales of $3.58 Million

Wall Street analysts forecast that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will report $3.58 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for BioCryst Pharmaceuticals’ earnings, with the highest sales estimate coming in at $6.96 million and the lowest estimate coming in at $440,000.00. BioCryst Pharmaceuticals posted sales of $3.89 million during the same quarter last year, which would indicate a negative year over year growth rate of 8%. The firm is expected to report its next quarterly earnings results on Tuesday, February 26th.

According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full-year sales of $21.87 million for the current year, with estimates ranging from $17.34 million to $28.05 million. For the next financial year, analysts expect that the firm will report sales of $12.91 million, with estimates ranging from $1.70 million to $19.18 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.03). The business had revenue of $1.45 million during the quarter, compared to analyst estimates of $2.53 million. BioCryst Pharmaceuticals had a negative net margin of 270.95% and a negative return on equity of 107.85%.

A number of brokerages have recently issued reports on BCRX. JMP Securities raised their price target on shares of BioCryst Pharmaceuticals from $12.00 to $16.00 and gave the stock an “outperform” rating in a report on Wednesday, September 5th. BidaskClub lowered shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 9th. HC Wainwright restated a “buy” rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, August 13th. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 10th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $8.50 price objective on shares of BioCryst Pharmaceuticals in a research note on Thursday, August 9th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. BioCryst Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $9.89.

Shares of NASDAQ BCRX traded up $0.17 during midday trading on Friday, reaching $7.94. 275,423 shares of the stock were exchanged, compared to its average volume of 428,437. The company has a market capitalization of $875.66 million, a P/E ratio of -10.17 and a beta of 1.75. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.25 and a quick ratio of 1.25. BioCryst Pharmaceuticals has a twelve month low of $4.25 and a twelve month high of $8.13.

In other news, insider Thomas R. Staab II sold 9,850 shares of the business’s stock in a transaction dated Wednesday, October 3rd. The shares were sold at an average price of $7.24, for a total transaction of $71,314.00. Following the transaction, the insider now directly owns 140,633 shares in the company, valued at $1,018,182.92. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Thomas R. Staab II sold 10,856 shares of the business’s stock in a transaction dated Friday, November 2nd. The stock was sold at an average price of $7.84, for a total transaction of $85,111.04. Following the transaction, the chief financial officer now owns 144,739 shares in the company, valued at $1,134,753.76. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 88,000 shares of company stock worth $631,613. 4.50% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC boosted its holdings in BioCryst Pharmaceuticals by 45.0% during the second quarter. Janus Henderson Group PLC now owns 11,096,183 shares of the biotechnology company’s stock worth $63,581,000 after buying an additional 3,441,498 shares in the last quarter. BlackRock Inc. boosted its holdings in BioCryst Pharmaceuticals by 3.8% during the second quarter. BlackRock Inc. now owns 7,755,951 shares of the biotechnology company’s stock worth $44,442,000 after buying an additional 281,532 shares in the last quarter. VHCP Management II LLC boosted its holdings in BioCryst Pharmaceuticals by 11.0% during the second quarter. VHCP Management II LLC now owns 2,464,241 shares of the biotechnology company’s stock worth $14,120,000 after buying an additional 243,270 shares in the last quarter. Northern Trust Corp boosted its holdings in BioCryst Pharmaceuticals by 2.2% during the second quarter. Northern Trust Corp now owns 1,214,561 shares of the biotechnology company’s stock worth $6,960,000 after buying an additional 25,685 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its holdings in BioCryst Pharmaceuticals by 5.7% during the second quarter. Schwab Charles Investment Management Inc. now owns 519,060 shares of the biotechnology company’s stock worth $2,975,000 after buying an additional 28,084 shares in the last quarter. Institutional investors and hedge funds own 79.82% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.

See Also: How to calculate compound interest

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply